The 13 C-mixed triacylglycerol (MTG) breath test is used to measure intraluminal fat digestion. In normal digestion 20% to 40% of the ingested 13 C label is recovered in breath CO 2 . We aimed to identify the proportions of ingested label excreted in stool as well as breath following ingestion of 13 C-MTG by children with impaired exocrine pancreatic function and healthy controls. 13 C enrichment of breath samples was measured by continuous flow isotope ratio mass spectrometry (IRMS) and the cumulative percent dose recovered (cPDR) in 10 hours was calculated. Total 13 C of a fecal fat extract from each stool was measured by combustion-IRMS, and 13 C enrichment and concentration of the tert.-butyldimethylsilyl (TBDMS) derivative of octanoic acid was measured by gas chromatography-mass spectrometry (GC/MS) after hydrolysis of the fat extract. Stool 5-day cPDR was calculated. Mean breath cPDR was 33% for children with cystic fibrosis and 45% for controls. Mean cPDR in stool by combustion-IRMS and GC/MS, respectively, was 0.7% and 0.3% for children with cystic fibrosis and 1.4 and 4.2% for controls.
Introduction
C-breath tests have become useful non-invasive tools to measure gastrointestinal functions and to monitor pharmacological and nutritional interventions [1] .
Labeling of nutritional substrates with 13 C enables investigation of their digestion, absorption, and subsequent metabolism. The labeled compound is taken by mouth, usually as part of a test meal. Thereafter it is digested, absorbed, oxidized and the label appears in breath carbon dioxide (CO 2 ). 13 C-breath tests are particularly attractive for use in children.
The 13 C-mixed triacylglycerol ( 13 C-MTG) breath test has been used to measure intraluminal fat digestion [2] [3] [4] . 1,3 distearyl 2-[1-13 C] octanoyl-glycerol (MTG) is composed of two long-chain saturated fatty acids (C18:0, stearic acid) at the sn-1 and -3 positions, and a medium-chain fatty acid (octanoic acid) at the sn-2 position of the triacylglycerol. Pancreatic lipases preferentially hydrolyze triglycerol at the sn-1 and -3 positions, after which the octanoate is rapidly absorbed and oxidized with release of 13 CO 2 . In normal digestion 20% to 40% of the 13 C label is excreted in breath CO 2 [2] . It is not known what proportion of the other 60% to 80% is excreted in stool, or remains after digestion and absorption, in slow-turnover carbon pools within the body. The aim of this study was to identify the proportions of ingested label excreted in stool as well as breath following ingestion of 13 C-MTG by children with impaired exocrine pancreatic function. Bulk analysis of stool lipid 13 C was compared with compound specific analysis of 13 C-octanoic acid in stool.
Methods

Subjects and procedures
The study was performed at the Royal Hospital for Sick Children in Glasgow with the informed consent of the children and their parents and the approval of the hospital ethics committee. After an overnight fast, eight children with cystic fibrosis (CF) and two healthy controls ingested 20 mg/kg (CF) or 10 mg/kg (control) 13 C-MTG (99 atom% excess 13 C, Cambridge Isotope Laboratories, Andover, MA, USA) with a standard breakfast (whole wheat, low sugar breakfast cereal, milk, and beet sugar; about 170 kcal and 7.7g fat), and their normal enzyme replacement therapy. The subjects were asked to avoid foods that are naturally enriched in 13 C, e.g., maize, maize products and foods containing cane sugar, for 24 hours prior to the test, and they remained at rest during the test [5] . Breath samples were collected at baseline, half-hourly for six hours, and hourly for four more hours. CO 2 production rate (VCO2) was measured hourly during the breath sampling period using a ventilated hood indirect calorimeter (Deltatrac II, Datex, Helsinki, Finland) [6] . All stools were collected before and for five days after 13 C-MTG ingestion. Stool wet weight was noted and the samples frozen immediately. 13 C enrichment of breath samples was measured by continuous flow isotope ratio mass spectrometry (CF-IRMS, Hydra, PDZ Europa, Crewe, UK) with reference to a standard gas (3% CO 2 in N 2 , Air Products, Crewe, UK), which had been calibrated against international standards [7] . Instantaneous percentage dose recovered (PDR/h) was calculated using the following equation.
Breath 13 C analysis
The cumulative percent dose recovered in breath (cPDR) was then calculated by integrating instantaneous PDR values over the 10 hour sampling period.
Stool lipid extraction
Lipid was extracted from 0.5g of freeze-dried stool by the method of Jeejeebhoy [8] , as described by Slater [9] which ensures good recovery of medium chain fatty acids. One-fourth of the solvent extract was dried under nitrogen gas and weighed to give lipid yield, 25% was frozen for bulk 13 C analysis, 25% had internal standards added (nonanoic acid and tri-pentadecanoin (Sigma-Aldrich, Poole, UK) at concentrations expected for octanoic acid, and heptadecanoic acid (Sigma-Aldrich, Poole, UK) at the palmitate level), and was stored at -20°C for compound specific analysis of 13 C octanoic acid. An external standard, containing 13 C-MTG, internal standards, unlabeled octanoic acid and fatty acids in the relative proportions found in stool [10] was stored with the samples to check for losses during storage.
Bulk analysis of stool lipid 13 C
Stool lipid extract containing approximately 2 mg C was pipetted into 150 µl capacity tin boats (8 × 5 mm, Elemental Microanalysis Ltd., Okehampton, UK) containing 20 µl 0.1M di-sodium tetraborate (BDH, Analar grade, Merck, Lutterworth, UK) and an inert support (acid washed Chromosorb W, mesh size 60/80, Alltech Associates, Carnforth, UK), which had been pre-combusted at 450°C for two hours to remove residual carbon. The solvent was removed by drying slowly in a refrigerator overnight and then freeze-drying for two hours. This procedure prevented the sample 'creeping' up the sides of the combustion boat and loss of any free octanoic acid. Stool lipid 13 C abundance and total carbon content were analyzed by CF-IRMS (Europa Scientific 20-20 with a biological sample converter [11] , PDZ Europa, Crewe, UK). The oxidation stage was held at 980°C, the reduction stage was 550°C, and the gas chromatograph column was held at 75°C. The system was calibrated using beet sucrose, whose 13 C enrichment had been independently calibrated against an international standard. The 13 C enrichment of the samples was calculated by comparison with working standards comprising 2.375 mg beet sucrose (containing 1 mg C), after subtraction of the blank consisting of a combustion boat with Chromosorb W. The percent dose recovered in each stool sample was calculated and these were summed to determine stool 5-day cPDR.
Compound-specific analysis of stool 13 C-octanoic acid
Lipid extract equivalent to 5 mg fat was dried under N 2 , hydrolyzed using methanolic NaOH, acidified and extracted into 2 ml iso-octane. The tert.-butyldimethylsilyl (TBDMS) derivative of the fatty acids was prepared [9] . TBDMS fatty acid enrichment and concentration were analyzed by gas chromatographymass spectrometry (GC/MS, Hewlett Packard 5890 II GC with an Optic temperature programmable injector, Fisons Instruments A200S autosampler and VG Trio-1000 quadrupole MS with electron impact ionisation, all supplied by Fisons Instruments, Middlewich, UK).
The gas chromatograph was operated in splitless mode with helium (CP grade) as the carrier gas. The injector temperature was initially 80°C, with a 0.75 minutes hold, then ramped to 300°C at 16°C s -1 . The transfer line between the GC and the MS was operated at 300°C. The analytical column was a DB5ms (J & W Scientific, Folsom, Calif., USA), length: 30 m, internal diameter 0.25 mm, film thickness 0.25 µm. The temperature program started at 80°C and ramped to 240°C at 20° minutes -1 , then from 220°C to 256°C at 2° minutes -1 , and finally from 256°C to 320°C at 20° minutes -1 , followed by 30s at 320°C. The solvent delay was 5 minutes. The injection volume was initially 0.2 µL.
The Trio-1000 quadrupole mass spectrometer with electron impact ionization was operated with a trap current of 150 µA and electron energy of -70eV. The source temperature was 200°C, and the detector multiplier was operated at 300 V. The TBDMS derivative has a prominent ion at M-57, i.e., M-(C-(CH 3 ) 3 and a much smaller ion at M-15, i.e., M-CH 3 . As there was very little octanoic acid in the samples, selected-ion recording mode of M-57 was used to measure TBDMSoctanoic acid enrichment and concentration, and M-15 was used for the other fatty acids. This enabled the analysis of nmoles octanoic acid in the presence of µmoles of other fatty acids. The quantitation masses for octanoic acid and 13 C-octanoic acid were m/z 201 and 202 (M-57). M-15 was monitored for all other fatty acids including m/z 257 for nonanoic acid and m/z 341 for pentadecanoic acid, the internal standards. The dwell time on each mass was 0.08 seconds, with a span of ± 0.1 amu (atomic mass unit).
Samples were screened to determine how much octanoic acid was in each and then re-injected at optimum volume in order to match the amount of octanoic acid in baseline and post-dose samples to avoid problems arising from subtracting the wrong background correction. This will be discussed later. Concentration of octanoic acid was calculated with reference to the internal standards, and related to the wet weight of stool. As any octanoic acid present was relatively highly enriched, the sum of the ion beams at m/z 201 and 202 was divided by that of the internal standard and related to the response factor of the external standard to determine the amount of octanoic acid in the lipid extract. From this, the concentration of octanoic acid in the original sample was calculated. Enrichment of 1-13 C-octanoic acid (mole percent excess, MPE) was calculated from the background corrected ratio of 202/201 according to the following equation.
where R E and R B are the observed ion beam ratios (202/201) of the enriched and baseline samples, respectively.
The PDR in each stool sample was calculated from the product of concentration and enrichment, divided by the product of the MTG dose and enrichment. These were summed to determine stool 5-day cPDR.
The non-esterified fatty acid (NEFA) and triacylglycerol (TAG) fractions of the lipid extract were separated by solid phase extraction (Bond Elute 200 mg amino propyl columns, International Sorbent Technology, Hengoed, Mid Glamorgan, UK) [12] in samples from two subjects with a relatively large amount of octanoic acid.
Results and discussion
The mean (SD) cPDR in breath 13 CO 2 was 33 (13)% for children with CF and 45% for controls. This is comparable with previous studies [2] . The results for individual subjects are shown in table 1. Bulk analysis of 13 C in the stool lipid extract showed that very little tracer was recovered in stool (cPDR was 0.7 (0.6)%, mean (SD), for children with CF and 1.4% for controls). Extracted lipids were analyzed in preference to whole, homogenized stool because lipid extracts can be analyzed with better precision and greater sensitivity [9] . Compound specific analysis of 13 C-octanoic acid showed that there was a median of 6 µmole octanoic acid per stool, compared to about 3 mmole palmitate in our previous study [9] . At very low concentration, the measured ratio (m/z 202:201) of natural abundance samples increases compared to the ratio calculated from the natural abundance of the constituent isotopes ( fig. 1 ). Subtraction of the wrong baseline can thus lead to erroneous results when calculating enrichment. At higher sample concentration, the measured ratio is close to the theoretical ratio. Use of matching baseline and enriched samples as described above avoids these problems. The stool cPDR measured by GC/MS was 0.3 (0.2)%, mean (SD), for children with cystic fibrosis and 4.2% for controls.
We are not aware of any other reports of 13 C-MTG measurements in stool, but the results presented here agree well with those of Murphy et al. [13] , who used 13 C-labeled tripalmitin to study gastrointestinal handling of lipids in children recovering from severe malnutrition. When normal nutritional status was achieved, i.e., weight-for-height had reached 90% of the reference, 1.4 (0.4-2.5)% of dietary lipid was found in stool. These data were obtained by bulk 13 C analysis of whole, freeze-dried stool. In children with severe malnutrition, the tracer in stool was present in the form of undigested triacylglycerol, but after recovery the label was found as non-esterified fatty acid. The label in MTG is on a medium chain fatty acid, octanoic acid, which is rapidly absorbed directly into the portal circulation and therefore behaves differently from long chain fatty acids. The 13 C-MTG test is therefore a test of digestion, rather than absorption.
Given the difficulty of measuring very low amounts of stool 13 C lipid, the two analytical methods agree reasonably well. IRMS measures total 13 C and analysis of hydrolyzed lipid extract by GC/MS measures 13 C-octanoic acid, therefore most 13 C must be in the form of free or esterified octanoic acid. Solid phase extraction of the lipid extract from two subjects with a relatively large amount of octanoic acid, showed that it was mainly in the form of undigested triacylglycerol. Thus, there is no evidence of substantial modification by colonic microflora.
Conclusions
Ingestion of 13 C-MTG by children with cystic fibrosis on their normal enzyme replacement therapy is followed by almost complete intestinal digestion and absorption of the substrate. The 13 C label not identified in breath must remain in the body, and the variation of cPDR in breath is therefore due largely to factors other than efficiency of lipolysis.
